摘要
目的探讨冠心病合并脑梗塞患者的临床治疗。方法选取在院治疗的60例冠心病合并脑梗塞的患者,随机分为实验组和对照组,每组30例,实验组运用依达拉奉联合通心络治疗,对照组采用依达拉奉治疗,治疗期间分析两组患者的血脂、心肌酶及欧洲卒中评分的变化。结果两组经药物治疗后,患者的血脂、心肌酶及欧洲卒中评分水平均有所改善,但是经依达拉奉联合通心络胶囊治疗的效果更好。结论经依达拉奉联合通心络胶囊治疗冠心病合并脑梗塞的治疗效果较好,能有效改善机体血脂及心肌酶水平,减轻神功功能的损伤。
Objective To study the treatment of coronary heart disease(CHD) combined cerebral infarction. Methods Chosen 60 CHD combined cerebral infarction,randomly divided into experimental group and control group,each group had 30 people,the experimental group used edaravone combined tongxinluo,and the control used only edaravone,analysis two sets of patients blood fat,myocardial enzyme and European stroke score changes during treatment period. Results The drug therapy,the patient's blood fat,myocardial enzyme and European stroke score level of two groups were improved,but the treatment effect of edaravone combined tongxinluo capsule was better. Conclusion The treatment effect of edaravone combined tongxinluo capsule to CHD combined cerebral infarction was good,can effectively improve the body blood fat and myocardial enzyme levels,reduce nerve function damage.
出处
《中外医疗》
2013年第10期7-7,10,共2页
China & Foreign Medical Treatment
关键词
冠心病
脑梗塞
依达拉奉
通心络
Coronary heart disease
Cerebral infarction
Edaravone
Tongxinluo